Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.
Johnson & Johnson reported better-than-expected third-quarter sales and raised its full-year revenue guidance.
Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated ...
Though psoriasis affects people of all skin tones, that diversity isn’t always represented in portrayals of the condition in ...
Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.
David Risinger, an analyst from Leerink Partners, maintained the Buy rating on Johnson & Johnson (JNJ – Research Report). The ...
Naturally, much of the near 10-minute discussion was focused on the defense and its struggles. Just one year after leading ...
Two candidates from North Central Florida are running for the Florida House of Representatives District 22 seat.
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Dwayne Johnson has previewed his "wild" festive blockbuster Red One ahead of its theatrical release next month. Also ...
A Springfield resident and local real estate entrepreneur, Evan Plotkin has just been awarded $15 million after a jury found ...